The Role of Metabolic Imaging in Radiation Therapy of Prostate Cancer

Overview

Journal NMR Biomed

Publisher Wiley

Date 2013 Aug 14

PMID 23940096

Citations 9

Authors

V Y Zhang

A Westphalen

L Delos Santos

Z L Tabatabai

K Shinohara

D B Vigneron

J Kurhanewicz

Affiliations

Soon will be listed here.

Abstract

The goal of this study was to correlate prostatic metabolite concentrations from snap-frozen patient biopsies of recurrent cancer after failed radiation therapy with histopathological findings, including Ki-67 immunohistochemistry and pathologic grade, in order to identify quantitative metabolic biomarkers that predict for residual aggressive versus indolent cancer. A total of 124 snap-frozen transrectal ultrasound (TRUS)-guided biopsies were acquired from 47 men with untreated prostate cancer and from 39 men with a rising prostate-specific antigen and recurrent prostate cancer following radiation therapy. Biopsy tissues with Ki-67 labeling index ≤ 5% were classified as indolent cancer, while biopsy tissues with Ki-67 labeling index > 5% were classified as aggressive cancer. The majority (15 out of 17) of cancers classified as aggressive had a primary Gleason 4 pattern (Gleason score ≥ 4 + 3). The concentrations of choline-containing phospholipid metabolites (PC, GPC, and free Cho) and lactate were significantly elevated in recurrent cancer relative to surrounding benign tissues. There was also a significant increase in [PC] and reduction in [GPC] between untreated and irradiated prostate cancer biopsies. The concentration of the choline-containing phospholipid metabolites was significantly higher in recurrent aggressive (≈ twofold) than in recurrent indolent cancer biopsies, and the receiver operating characteristic (ROC) curve analysis of total choline to creatine ratio (tCho/Cr) demonstrated an accuracy of 95% (confidence interval = 0.88-1.00) for predicting aggressive recurrent disease. The tCho/Cr was significantly higher for identifying recurrent aggressive versus indolent cancer (tCho/Cr = 2.4 ± 0.4 versus 1.5 ± 0.2), suggesting that use of a higher threshold tCho/Cr ratio in future in vivo (1)H MRSI studies could improve the selection and therapeutic planning for patients who would benefit most from salvage focal therapy after failed radiation therapy.

Citing Articles

Metabolomic profiles of intact tissues reflect clinically relevant prostate cancer subtypes.

Dudka I, Lundquist K, Wikstrom P, Bergh A, Grobner G J Transl Med. 2023; 21(1):860.

PMID: 38012666 PMC: 10683247. DOI: 10.1186/s12967-023-04747-7.

Development trends and knowledge framework in the application of magnetic resonance imaging in prostate cancer: a bibliometric analysis from 1984 to 2022.

Ye Y, Liu Z, Zhu J, Wu J, Sun K, Peng Y Quant Imaging Med Surg. 2023; 13(10):6761-6777.

PMID: 37869318 PMC: 10585509. DOI: 10.21037/qims-23-446.

Three-dimensional nuclear magnetic resonance spectroscopy: a complementary tool to multiparametric magnetic resonance imaging in the identification of aggressive prostate cancer at 3.0T.

Deal M, Bardet F, Walker P, Vega M, Cochet A, Cormier L Quant Imaging Med Surg. 2021; 11(8):3749-3766.

PMID: 34341747 PMC: 8245930. DOI: 10.21037/qims-21-331.

Magnetic resonance biomarkers in radiation oncology: The report of AAPM Task Group 294.

McGee K, Hwang K, Sullivan D, Kurhanewicz J, Hu Y, Wang J Med Phys. 2021; 48(7):e697-e732.

PMID: 33864283 PMC: 8361924. DOI: 10.1002/mp.14884.

Simultaneous Metabolic and Perfusion Imaging Using Hyperpolarized C MRI Can Evaluate Early and Dose-Dependent Response to Radiation Therapy in a Prostate Cancer Mouse Model.

Qin H, Zhang V, Bok R, Delos Santos R, Cunha J, Hsu I Int J Radiat Oncol Biol Phys. 2020; 107(5):887-896.

PMID: 32339646 PMC: 7381368. DOI: 10.1016/j.ijrobp.2020.04.022.

References

Bong G, Keane T . Salvage options for biochemical recurrence after primary therapy for prostate cancer. Can J Urol. 2008; 14 Suppl 1:2-9. View

Hanlon A, Diratzouian H, Hanks G . Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys. 2002; 53(2):297-303. DOI: 10.1016/s0360-3016(02)02717-7. View

Mostofi F, Sesterhenn I, Davis Jr C . A pathologist's view of prostatic carcinoma. Cancer. 1993; 71(3 Suppl):906-32. DOI: 10.1002/1097-0142(19930201)71:3+<906::aid-cncr2820711407>3.0.co;2-i. View

Westphalen A, Kurhanewicz J, Cunha R, Hsu I, Kornak J, Zhao S . T2-Weighted endorectal magnetic resonance imaging of prostate cancer after external beam radiation therapy. Int Braz J Urol. 2009; 35(2):171-80. PMC: 4532331. DOI: 10.1590/s1677-55382009000200007. View

Westphalen A, Coakley F, Roach 3rd M, McCulloch C, Kurhanewicz J . Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection. Radiology. 2010; 256(2):485-92. PMC: 2909433. DOI: 10.1148/radiol.10092314. View

Kuban D, Schellhammer P . The significance of post-irradiation prostate biopsy with long-term follow-up. Int J Radiat Oncol Biol Phys. 1992; 24(3):409-14. DOI: 10.1016/0360-3016(92)91053-p. View

Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M . Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys. 2000; 48(2):355-67. DOI: 10.1016/s0360-3016(00)00637-4. View

Foltz W, Wu A, Chung P, Catton C, Bayley A, Milosevic M . Changes in apparent diffusion coefficient and T2 relaxation during radiotherapy for prostate cancer. J Magn Reson Imaging. 2012; 37(4):909-16. DOI: 10.1002/jmri.23885. View

Albers M, Bok R, Chen A, Cunningham C, Zierhut M, Zhang V . Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res. 2008; 68(20):8607-15. PMC: 2829248. DOI: 10.1158/0008-5472.CAN-08-0749. View

10.

Bhujwalla Z, Aboagye E, Gillies R, Chacko V, Mendola C, Backer J . Nm23-transfected MDA-MB-435 human breast carcinoma cells form tumors with altered phospholipid metabolism and pH: a 31P nuclear magnetic resonance study in vivo and in vitro. Magn Reson Med. 1999; 41(5):897-903. DOI: 10.1002/(sici)1522-2594(199905)41:5<897::aid-mrm7>3.0.co;2-t. View

11.

Swanson M, Keshari K, Tabatabai Z, Simko J, Shinohara K, Carroll P . Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy. Magn Reson Med. 2008; 60(1):33-40. PMC: 2643975. DOI: 10.1002/mrm.21647. View

12.

Heerschap A, Jager G, van der Graaf M, Barentsz J, Ruijs S . Proton MR spectroscopy of the normal human prostate with an endorectal coil and a double spin-echo pulse sequence. Magn Reson Med. 1997; 37(2):204-13. DOI: 10.1002/mrm.1910370212. View

13.

Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P . Percent Gleason grade 4/5 as prognostic factor in prostate cancer diagnosed at transurethral resection. J Urol. 2002; 168(2):509-13. View

14.

Kim C, Park B, Lee H . Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI. J Magn Reson Imaging. 2009; 29(2):391-7. DOI: 10.1002/jmri.21645. View

15.

Sala E, Eberhardt S, Akin O, Moskowitz C, Onyebuchi C, Kuroiwa K . Endorectal MR imaging before salvage prostatectomy: tumor localization and staging. Radiology. 2005; 238(1):176-83. DOI: 10.1148/radiol.2381052345. View

16.

Pickett B, Kurhanewicz J, Pouliot J, Weinberg V, Shinohara K, Coakley F . Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level. Int J Radiat Oncol Biol Phys. 2006; 65(1):65-72. DOI: 10.1016/j.ijrobp.2005.11.037. View

17.

Naressi A, Couturier C, Devos J, Janssen M, Mangeat C, de Beer R . Java-based graphical user interface for the MRUI quantitation package. MAGMA. 2001; 12(2-3):141-52. DOI: 10.1007/BF02668096. View

18.

Walenta S, Chau T, Schroeder T, Lehr H, Kunz-Schughart L, Fuerst A . Metabolic classification of human rectal adenocarcinomas: a novel guideline for clinical oncologists?. J Cancer Res Clin Oncol. 2003; 129(6):321-6. DOI: 10.1007/s00432-003-0450-x. View

19.

Pickett B, Ten Haken R, Kurhanewicz J, Qayyum A, Shinohara K, Fein B . Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging. Int J Radiat Oncol Biol Phys. 2004; 59(3):665-73. DOI: 10.1016/j.ijrobp.2003.11.024. View

20.

Day S, Kettunen M, Cherukuri M, Mitchell J, Lizak M, Morris H . Detecting response of rat C6 glioma tumors to radiotherapy using hyperpolarized [1- 13C]pyruvate and 13C magnetic resonance spectroscopic imaging. Magn Reson Med. 2011; 65(2):557-63. PMC: 3690628. DOI: 10.1002/mrm.22698. View